Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.32)
# 940
Out of 5,182 analysts
68
Total ratings
53.19%
Success rate
15.3%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Neutral | $100 → $105 | $89.79 | +16.94% | 5 | Feb 3, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $12.79 | +56.37% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $75.34 | +0.88% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $7.90 | +77.22% | 1 | Aug 4, 2025 | |
| ILMN Illumina | Maintains: Neutral | $85 → $100 | $120.93 | -17.31% | 1 | Aug 1, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $18.05 | +71.75% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $23.27 | -61.32% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $47.91 | -31.12% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $120.10 | +58.20% | 6 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $26.39 | -28.00% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $380 → $390 | $320.00 | +21.88% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $42.94 | +28.09% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $78.60 | -30.03% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $115.06 | +39.06% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $496.11 | +35.05% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $4.35 | +359.77% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,325.01 | +5.66% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.34 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $37.59 | +139.43% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $189.61 | +42.40% | 4 | Dec 20, 2023 |
Revvity
Feb 3, 2026
Maintains: Neutral
Price Target: $100 → $105
Current: $89.79
Upside: +16.94%
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $12.79
Upside: +56.37%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $75.34
Upside: +0.88%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $7.90
Upside: +77.22%
Illumina
Aug 1, 2025
Maintains: Neutral
Price Target: $85 → $100
Current: $120.93
Upside: -17.31%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $18.05
Upside: +71.75%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $23.27
Upside: -61.32%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $47.91
Upside: -31.12%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $120.10
Upside: +58.20%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $26.39
Upside: -28.00%
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $320.00
Upside: +21.88%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $42.94
Upside: +28.09%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $78.60
Upside: -30.03%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $115.06
Upside: +39.06%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $496.11
Upside: +35.05%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $4.35
Upside: +359.77%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,325.01
Upside: +5.66%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.34
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $37.59
Upside: +139.43%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $189.61
Upside: +42.40%